Sinovac Completed its 23-Valent Pneumococcal Polysaccharide Vaccine Phase III Clinical Trial and Filed the New Drug Application to CFDA

Stock Information for Sinovac Biotech Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sinovac Biotech Ltd.

Sinovac Raises $86.73 Million Through Private Placement Transaction
Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court
Sinovac Biotech Relaunches Company Website
Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial Results
Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
Sinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection
Sinovac Temporarily Blocks Access to Its Websites

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.